Ulocuplumab 产品活性：Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) 是一种完全人 IgG4 抗 CXCR4 抗体。Ulocplumab 诱导癌细胞凋亡 (apoptosis)，能够抑制 CXCL12 介导的慢性淋巴细胞白血病 (CLL) 细胞在 CXCR4 激活下的迁移。Ulocplumab 在急性髓系白血病 (AML)，非霍奇金淋巴瘤 (NHL) 和多发性骨髓瘤移植模型中显示抗肿瘤活性。 产品来源： https://www.medchemexpress.cn/ulocuplumab.html 研究领域：GPCR/G Protein | Immunology/Inflammation 作用靶点：CXCR In Vitro: Ulocuplumab (0-100 μM; 48 h) lacks antibody dependent cellular cytotoxicity (ADCC) or complement (CDC) activity, but also induces apoptosis mediated by CXCR4 binding in Ramos cells and CLL/cancer cell lines, also shows pro-apoptotic in primary leukemia cells from CLL patients. Ulocuplumab (0.2 μM and 2 μM; 15 s) inhibits F-actin polymerization and reduces the peak response to CXCL12, and also (20 nM-2 μM; 1 h) inhibits cell migration. Ulocuplumab (200 nM; 6 h) leads to induction of programmed cell death (PCD) is caspase independent. Ulocuplumab (10 μg/mL; 4 h) induces cell death via production of reactive oxygen species (ROS) in CLL cells. Ulocuplumab inhibits CXCL12-induced calcium flux with an EC50 value of 10 nM in Ramos. In Vivo: Ulocuplumab (3-30 mg/kg; i.p.; every 3-4 days for 5 doses; 65 days in total) inhibits tumor growth of multiple myeloma xenograft models in mice, including Ramos B cells, HL-60 cells, MOLP-8 cells, Nomo-1 cells, and JJN-3R cells models. 相关产品：Plerixafor | SB225002 | AMG 487 | Reparixin | Kynurenic acid | Navarixin | AZD8797 | AZD-5069 | Motixafortide | TAK-779 | Mavorixafor trihydrochloride | SCH 546738 | Baohuoside I | SX-682 | ACT-1004-1239 | Decursin | Ladarixin | ML339 | NUCC-390 dihydrochloride | NBI-74330 | SB-265610 | VUF11207 fumarate | CXCR7 antagonist-1 | ML 145 | IT1t dihydrochloride | Danirixin | PS372424 hydrochloride | WZ811 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。